Diabetes research and clinical practice · 2026
Impact of sodium-glucose cotransporter-2 inhibitors on clinical outcomes in patients with type 1 diabetes after dialysis-requiring acute kidney injury: a real-world cohort study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Chung-An, Wang Wei-Jie, Chen Jui-Yi, Jiang Zheng-Hong, Wu Vin-Cent
Аннотация
AIMS: Sodium-glucose cotransporter-2 inhibitors (SGLT-2is) have shown significant cardiovascular and kidney benefits, but their role in T1D with acute kidney disease (AKD) remains uncertain.
METHODS: This propensity-score matching cohort study utilized data from the TriNetX Network, including patients aged ≥18 years with T1D after dialysis requiring acute kidney disease (AKI) and were discharged from hospitals between 2012 and 2024. The primary outcomes were all-cause mortality, major adverse kidney events (MAKEs), and major adverse cardiovascular events (MACEs), analyzed using Cox proportional hazards regression models.
RESULTS: Among 16,680 patients with T1D and AKD, 614 (3.74%) patients received SGLT-2is, and matched with non-users. After a median follow-up of 1.7 years, SGLT-2i use was associated with lower all-cause mortality (aHR, 0.49; 95% CI, 0.36-0.71) and MAKEs (aHR, 0.53; 95% CI, 0.34-0.82), but no significant difference in MACEs (aHR, 0.86; 95% CI, 0.59-1.25). Genital infections and volume depletion were more frequent, without significant increase in diabetic ketoacidosis, urinary tract infections, or hypoglycemia.
CONCLUSIONS: In this study, SGLT-2i use was associated with improved kidney outcomes and reduced all-cause mortality in T1D patients with AKD. These findings suggest potential kidney and survival benefits, warranting further prospective validation.
METHODS: This propensity-score matching cohort study utilized data from the TriNetX Network, including patients aged ≥18 years with T1D after dialysis requiring acute kidney disease (AKI) and were discharged from hospitals between 2012 and 2024. The primary outcomes were all-cause mortality, major adverse kidney events (MAKEs), and major adverse cardiovascular events (MACEs), analyzed using Cox proportional hazards regression models.
RESULTS: Among 16,680 patients with T1D and AKD, 614 (3.74%) patients received SGLT-2is, and matched with non-users. After a median follow-up of 1.7 years, SGLT-2i use was associated with lower all-cause mortality (aHR, 0.49; 95% CI, 0.36-0.71) and MAKEs (aHR, 0.53; 95% CI, 0.34-0.82), but no significant difference in MACEs (aHR, 0.86; 95% CI, 0.59-1.25). Genital infections and volume depletion were more frequent, without significant increase in diabetic ketoacidosis, urinary tract infections, or hypoglycemia.
CONCLUSIONS: In this study, SGLT-2i use was associated with improved kidney outcomes and reduced all-cause mortality in T1D patients with AKD. These findings suggest potential kidney and survival benefits, warranting further prospective validation.